SIREN : 491617858
DILO MEDICAL is a French company founded 19 years ago, specialized in the sector Activités de conditionnement. Based in SAINTE-FOY-LES-LYON (69110), this company of category PME shows in 2024 a revenue of 1.1 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 056 715 € | 2 293 951 € | 269 242 € | 393 503 € | 686 445 € | 553 482 € | 574 618 € | 545 419 € | 514 768 € |
| Net income | -685 205 € | 186 016 € | 13 551 € | 13 368 € | 56 197 € | 39 800 € | 79 701 € | 57 396 € | 48 289 € |
| EBITDA | 30 762 € | 193 456 € | 5 867 € | 16 167 € | 46 689 € | 25 581 € | 60 357 € | 36 398 € | 38 472 € |
| Net margin | -64.8% | 8.1% | 5.0% | 3.4% | 8.2% | 7.2% | 13.9% | 10.5% | 9.4% |
In 2024, DILO MEDICAL achieves revenue of 1.1 M€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +9.4%. Significant drop of -54% vs 2023. After deducting consumption (274 k€), gross margin stands at 782 k€, i.e. a rate of 74%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 31 k€, representing 2.9% of revenue. Warning negative scissor effect: despite revenue change (-54%), EBITDA varies by -84%, reducing margin by 5.5 pts. This reflects costs rising faster than revenue. The operating margin remains fragile, requiring cost vigilance. Net income is negative at -685 k€ (-64.8% of revenue), which will impact equity.
1 056 715 €
782 323 €
30 762 €
14 319 €
-685 205 €
2.9%
The debt ratio (= Financial debt / Equity x 100) stands at 38%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 60%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 4.2 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 2.7% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
37.659%
59.957%
2.693%
4.223
5.4%
In 2024, the debt ratio of DILO MEDICAL (37.66) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of DILO MEDICAL (60.0%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2024, the repayment capacity of DILO MEDICAL (4.22) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.
The liquidity ratio (= Current assets / Current liabilities) stands at 765.46. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 2274.0x. Operating income very largely covers interest expenses: high safety margin.
765.456
2273.987
In 2024, the liquidity ratio of DILO MEDICAL (765.46) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of DILO MEDICAL (2274.0x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 19 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 18 days. The company must finance 1 days of gap between collections and payments. Inventory turnover is 22 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 40 days of revenue, i.e. 119 k€ to permanently finance.
118 785 €
19 j
18 j
22 j
40 j
Based on 158 transactions of similar company sales (all years), the value of DILO MEDICAL is estimated at 205 340 € (range 94 564€ - 416 736€). With an EBITDA of 30 762€, the sector multiple of 3.3x is applied. The price/revenue ratio is 0.36x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 158 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare DILO MEDICAL with other companies in the same sector:
Voir toutes les statistiques du secteur Activités de conditionnement
The revenue of DILO MEDICAL in 2024 is 1.1 M€.
DILO MEDICAL recorded a net loss in 2024.
The headquarters of DILO MEDICAL is located in SAINTE-FOY-LES-LYON (69110), in the department Rhone.
The tax return of DILO MEDICAL is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
DILO MEDICAL operates in the sector Activités de conditionnement (NAF code 82.92Z). See the 'Sector positioning' section above to compare the company with its competitors.